Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (cys‐mcMMAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathi, Chetan, Collins, Jon, Struemper, Herbert, Opalinska, Joanna, Jewell, Roxanne C., Ferron‐Brady, Geraldine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376139/
https://www.ncbi.nlm.nih.gov/pubmed/34076364
http://dx.doi.org/10.1002/psp4.12660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376139/
https://www.ncbi.nlm.nih.gov/pubmed/34076364
http://dx.doi.org/10.1002/psp4.12660

Ejemplares similares